Literature DB >> 11502769

A prospective investigation of quality of life and psychological well-being after the discontinuation of GH treatment in adolescent patients who had GH deficiency during childhood.

L Wirén1, G Johannsson, B A Bengtsson .   

Abstract

Some patients given growth-promoting therapy for GH deficiency in childhood will remain GH deficient in their adult lives and hence could benefit from continued GH replacement therapy. This longitudinal study sought to assess whether quality of life declines after GH discontinuation in late adolescence, and whether differences can be discerned in quality of life in patients whose GH deficiency persists into adulthood and those whose GH secretory capacity falls within normal ranges. Forty patients, aged 16-21 yr at baseline, were assessed over a 2-yr period commencing with discontinuation of GH therapy. Twenty-one patients were assigned to a GH deficiency group, and 19 were assigned to a GH-sufficient group. Quality of life assessments were made using the Nottingham Health Profile, Psychological General Well-Being Index, and Mood Adjective Check List Measures. Visual analog assessment of personality and affect and cognitive function tests were performed. The Mood Adjective Check List and visual analog assessments identified between-group and temporal changes in a limited number of the various personality domains assessed. The Psychological General Well-Being Index assessment indicated greater baseline impairment in the GH deficiency group than in the GH-sufficient group in overall score and in the domains of depression and general health. There was also a between-group difference in anxiety score at the 2-yr assessment, with the GH deficiency group having greater anxiety. Measurement of cognitive factors failed to reveal differences between groups. These results indicate that the discontinuation of GH therapy in late adolescence does not risk an immediate decline in the perceived quality of life detectable with the Nottingham Health Profile and Psychological General Well-Being Index measures. However, differences detected with the Mood Adjective Check List and visual analog assessments hint at clinically significant changes in the life experiences of adolescents discontinued from GH for which traditional measures may lack sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502769     DOI: 10.1210/jcem.86.8.7709

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Psychosocial effects of short stature.

Authors:  David Zlotkin; Surendra K Varma
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 2.  Growth hormone therapy and quality of life in adults and children.

Authors:  Deborah J Radcliffe; Joseph S Pliskin; J B Silvers; Leona Cuttler
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood.

Authors:  Grit Sommer; Micol E Gianinazzi; Rahel Kuonen; Julia Bohlius; Dagmar l'Allemand; Michael Hauschild; Primus-Eugen Mullis; Claudia E Kuehni
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

Review 4.  Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective.

Authors:  M Ahmid; S F Ahmed; M G Shaikh
Journal:  Ther Clin Risk Manag       Date:  2018-11-23       Impact factor: 2.423

5.  Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency.

Authors:  Christa C van Bunderen; Jan Berend Deijen; Madeleine L Drent
Journal:  Health Qual Life Outcomes       Date:  2018-07-06       Impact factor: 3.186

Review 6.  Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature.

Authors:  Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

Review 7.  Association of growth hormone deficiency (GHD) with anxiety and depression: experimental data and evidence from GHD children and adolescents.

Authors:  Fotini-Heleni Karachaliou; Kyriaki Karavanaki; Aristofania Simatou; Eleni Tsintzou; Nikitas S Skarakis; Christina Kanaka-Gatenbein
Journal:  Hormones (Athens)       Date:  2021-07-01       Impact factor: 2.885

Review 8.  Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement.

Authors:  M Ahmid; C G Perry; S F Ahmed; M G Shaikh
Journal:  Endocr Connect       Date:  2016-04-29       Impact factor: 3.335

9.  Maternal anxiety in relation to growth failure and growth hormone treatment in children.

Authors:  Katarzyna Anna Majewska; Maia Stanisławska-Kubiak; Katarzyna Wiecheć; Monika Naskręcka; Andrzej Kędzia; Ewa Mojs
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.